.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
US Army
Fish and Richardson
Citi
UBS
US Department of Justice
Cantor Fitzgerald
Mallinckrodt
Chinese Patent Office

Generated: September 19, 2017

DrugPatentWatch Database Preview

OFEV Drug Profile

« Back to Dashboard

Which patents cover Ofev, and when can generic versions of Ofev launch?

Ofev is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are three patents protecting this drug.

This drug has one hundred and seven patent family members in forty-three countries.

The generic ingredient in OFEV is nintedanib esylate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the nintedanib esylate profile page.

Summary for Tradename: OFEV

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list53
Clinical Trials: see list5
Patent Applications: see list25
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:OFEV at DailyMed

Pharmacology for Tradename: OFEV

Drug ClassKinase Inhibitor
Mechanism of ActionProtein Kinase Inhibitors
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim
OFEV
nintedanib esylate
CAPSULE;ORAL205832-001Oct 15, 2014RXYesNo► Subscribe► SubscribeYY ► Subscribe
Boehringer Ingelheim
OFEV
nintedanib esylate
CAPSULE;ORAL205832-002Oct 15, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Boehringer Ingelheim
OFEV
nintedanib esylate
CAPSULE;ORAL205832-001Oct 15, 2014RXYesNo► Subscribe► Subscribe► Subscribe
Boehringer Ingelheim
OFEV
nintedanib esylate
CAPSULE;ORAL205832-002Oct 15, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Boehringer Ingelheim
OFEV
nintedanib esylate
CAPSULE;ORAL205832-001Oct 15, 2014RXYesNo► Subscribe► SubscribeYY ► Subscribe
Boehringer Ingelheim
OFEV
nintedanib esylate
CAPSULE;ORAL205832-001Oct 15, 2014RXYesNo► Subscribe► Subscribe ► Subscribe
Boehringer Ingelheim
OFEV
nintedanib esylate
CAPSULE;ORAL205832-002Oct 15, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Boehringer Ingelheim
OFEV
nintedanib esylate
CAPSULE;ORAL205832-001Oct 15, 2014RXYesNo► Subscribe► Subscribe► Subscribe
Boehringer Ingelheim
OFEV
nintedanib esylate
CAPSULE;ORAL205832-002Oct 15, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Boehringer Ingelheim
OFEV
nintedanib esylate
CAPSULE;ORAL205832-002Oct 15, 2014RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: OFEV

Country Document Number Estimated Expiration
Denmark1224170► Subscribe
Slovenia1527047► Subscribe
MontenegroP45408► Subscribe
Germany19949208► Subscribe
Israel148756► Subscribe
World Intellectual Property Organization (WIPO)2004017948► Subscribe
Canada2493310► Subscribe
Peru06712001► Subscribe
Hungary230416► Subscribe
European Patent Office1527047► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: OFEV

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00725Netherlands► SubscribePRODUCT NAME: NINTEDANIB, DE TAUTOMEREN DAARVAN EN DE ZOUTEN DAARVAN, IN HET BIJZONDER NINTEDANIB EN FYSIOLOGISCH AANVAARDBARE ZOUTEN DAARVAN, MET NAME NINEDANIBESILAAT; REGISTRATION NO/DATE: EU/1/14/954/001-004 20141121
2015015,C1224170Lithuania► SubscribePRODUCT NAME: NINTEDANIBUM; REGISTRATION NO/DATE: EU/1/14/954/001-004 20141121
0725Netherlands► SubscribePRODUCT NAME: NINTEDANIB, DE TAUTOMEREN DAARVAN EN DE ZOUTEN DAARVAN, IN HET BIJZONDER NINTEDANIB EN FYSIOLOGISCH AANVAARDBARE ZOUTEN DAARVAN, MET NAME NINEDANIBESILAAT; REGISTRATION NO/DATE: EU/1/14/954/001-004 20141125
15/017Ireland► SubscribePRODUCT NAME: VARGATEF-NINTEDANIB, THE TAUTOMERS AND THE PHYSIOLOGICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/14/954/001-004 20141121
681Luxembourg► SubscribePRODUCT NAME: INDOLINONES SUBSTITUEES EN POSITION 6, LEUR PREPARATION ET LEUR UTILISATION EN TANT QUE MEDICAMENTS; FIRST REGISTRATION: 20141121
90015-2Sweden► SubscribePRODUCT NAME: NINTEDANIB, THE TAUTOMERS AND THE SALTS THEREOF, IN PARTICULAR NINTEDANIB AND PHYSIOLOGICALLY ACCEPTABLE SALTS THEREOF, SPECIFICALLY NINTEDANIB ESILATE; REG. NO/DATE: EU/1/14/954 20141121
C0024France► SubscribePRODUCT NAME: NINTEDANIB,SES TAUTOMERES ET SES SELS,EN PARTICULIER LES SELS PHYSIOLOGIQUEMENT ACCEPTABLES DE NINTEDANIB ET PLUS PARTICULIEREMENT L'ESILATE; REGISTRATION NO/DATE: EU/1/14/954 20141125
2015 00019Denmark► SubscribePRODUCT NAME: NINTEDANIB, TAUTOMERERNE OG SALTENE DERAF, SAERLIGT NINTEDANIB OG FYSIOLOGISK ACCEPTABLE SALTE DERAF, SPECIFIKT NINTEDANIB ESILAT; REG. NO/DATE: EU/1/14/954/001-004 20141121
8Finland► Subscribe
2015015Lithuania► SubscribePRODUCT NAME: NINTEDANIBUM; REGISTRATION NO/DATE: EU/1/14/954/001-004 20141121
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Johnson and Johnson
Harvard Business School
US Department of Justice
Merck
Teva
Chubb
Deloitte
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot